Prelude Therapeutics Past Earnings Performance
Past criteria checks 0/6
Prelude Therapeutics's earnings have been declining at an average annual rate of -23.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 114.4% per year.
Key information
-23.3%
Earnings growth rate
58.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 114.4% |
| Return on equity | -84.1% |
| Net Margin | -4,383.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Sep 16
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 09Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25Revenue & Expenses Breakdown
How Prelude Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3 | -132 | 30 | 117 |
| 30 Jun 24 | 0 | -130 | 29 | 114 |
| 31 Mar 24 | 0 | -126 | 29 | 109 |
| 31 Dec 23 | 0 | -122 | 29 | 103 |
| 30 Sep 23 | 0 | -117 | 29 | 99 |
| 30 Jun 23 | 0 | -117 | 30 | 96 |
| 31 Mar 23 | 0 | -114 | 30 | 92 |
| 31 Dec 22 | 0 | -115 | 31 | 93 |
| 30 Sep 22 | 0 | -120 | 31 | 92 |
| 30 Jun 22 | 0 | -120 | 32 | 92 |
| 31 Mar 22 | 0 | -120 | 29 | 93 |
| 31 Dec 21 | 0 | -112 | 27 | 87 |
| 30 Sep 21 | 0 | -98 | 24 | 76 |
| 30 Jun 21 | 0 | -84 | 19 | 69 |
| 31 Mar 21 | 0 | -69 | 15 | 56 |
| 31 Dec 20 | 0 | -57 | 11 | 48 |
| 30 Sep 20 | 0 | -48 | 7 | 42 |
| 30 Jun 20 | 0 | -38 | 6 | 33 |
| 31 Mar 20 | 0 | -32 | 4 | 28 |
| 31 Dec 19 | 0 | -28 | 4 | 24 |
Quality Earnings: PRLD is currently unprofitable.
Growing Profit Margin: PRLD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRLD is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare PRLD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRLD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: PRLD has a negative Return on Equity (-84.07%), as it is currently unprofitable.